BACKGROUND AND PURPOSE: Non-competitive drugs that confer allosteric modulation of orthosteric ligand binding are of increasing interest as therapeutic agents. Sought-after advantages include a ceiling level to drug effect and greater receptor-subtype selectivity. It is thus important to determine the mode of interaction of newly identified receptor ligands early in the drug discovery process and binding studies with labelled orthosteric ligands constitute a traditional approach for this. According to the general allosteric ternary complex model, allosteric ligands that exhibit negative cooperativity may generate distinctive 'competition' curves: they will not reach baseline levels and their nadir will increase in par with the orthosteric ligand concentration. This behaviour is often considered a key hallmark of allosteric interactions. EXPERIMENTAL APPROACH: The present study is based on differential equation-based simulations. KEY RESULTS: The differential equation-based simulations revealed that the same 'competition binding' pattern was also obtained when a monovalent ligand binds to one of the target sites of a heterobivalent ligand, even if this process is exempt of allosteric interactions. This pattern was not strictly reciprocal when the binding of each of the ligands was recorded. The prominence of this phenomenon may vary from one heterobivalent ligand to another and we suggest that this phenomenon may take place with ligands that have been proposed to bind according to 'two-domain' and 'charnière' models. CONCLUSIONS AND IMPLICATIONS: The present findings indicate a familiar experimental situation where bivalency may give rise to observations that could inadvertently be interpreted as allosteric binding. Yet, both mechanisms could be differentiated based on alternative experiments and structural considerations.
BACKGROUND AND PURPOSE: Non-competitive drugs that confer allosteric modulation of orthosteric ligand binding are of increasing interest as therapeutic agents. Sought-after advantages include a ceiling level to drug effect and greater receptor-subtype selectivity. It is thus important to determine the mode of interaction of newly identified receptor ligands early in the drug discovery process and binding studies with labelled orthosteric ligands constitute a traditional approach for this. According to the general allosteric ternary complex model, allosteric ligands that exhibit negative cooperativity may generate distinctive 'competition' curves: they will not reach baseline levels and their nadir will increase in par with the orthosteric ligand concentration. This behaviour is often considered a key hallmark of allosteric interactions. EXPERIMENTAL APPROACH: The present study is based on differential equation-based simulations. KEY RESULTS: The differential equation-based simulations revealed that the same 'competition binding' pattern was also obtained when a monovalent ligand binds to one of the target sites of a heterobivalent ligand, even if this process is exempt of allosteric interactions. This pattern was not strictly reciprocal when the binding of each of the ligands was recorded. The prominence of this phenomenon may vary from one heterobivalent ligand to another and we suggest that this phenomenon may take place with ligands that have been proposed to bind according to 'two-domain' and 'charnière' models. CONCLUSIONS AND IMPLICATIONS: The present findings indicate a familiar experimental situation where bivalency may give rise to observations that could inadvertently be interpreted as allosteric binding. Yet, both mechanisms could be differentiated based on alternative experiments and structural considerations.
Authors: Pierre De Meyts; Lisbeth Gauguin; Angela Manegold Svendsen; Mazen Sarhan; Louise Knudsen; Jane Nøhr; Vladislav V Kiselyov Journal: Ann N Y Acad Sci Date: 2009-04 Impact factor: 5.691
Authors: Tod Steinfeld; Mathai Mammen; Jacqueline A M Smith; Richard D Wilson; Jeffrey R Jasper Journal: Mol Pharmacol Date: 2007-05-03 Impact factor: 4.436
Authors: Andrew C Kruse; Aaron M Ring; Aashish Manglik; Jianxin Hu; Kelly Hu; Katrin Eitel; Harald Hübner; Els Pardon; Celine Valant; Patrick M Sexton; Arthur Christopoulos; Christian C Felder; Peter Gmeiner; Jan Steyaert; William I Weis; K Christopher Garcia; Jürgen Wess; Brian K Kobilka Journal: Nature Date: 2013-11-20 Impact factor: 49.962
Authors: Irina Kufareva; Martin Gustavsson; Yi Zheng; Bryan S Stephens; Tracy M Handel Journal: Annu Rev Biophys Date: 2017-05-22 Impact factor: 12.981
Authors: Romain Duroux; Antonella Ciancetta; Philip Mannes; Jinha Yu; Shireesha Boyapati; Elizabeth Gizewski; Said Yous; Francisco Ciruela; John A Auchampach; Zhan-Guo Gao; Kenneth A Jacobson Journal: Medchemcomm Date: 2017-06-22 Impact factor: 3.597